Mitoquinone

PreclinicalSmall molecule

OOregon Health and Science University

Mitoquinone is one of 41 small molecule programs targeting Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Multiple SclerosisActive, not recruiting

Breast CancerPreclinical

Active, not recruiting

Multiple SclerosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adriamycin

GGynecologic Oncology Group

Preclinical

87 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Chirocaine

PPurdue Pharma LP

Preclinical

1 4

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 5

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 6

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 7

Tetracycline Hydrochloride

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Preclinical

1 8

Leronlimab

CCytoDyn, Inc.

Preclinical

1 9

Lapatinib Plus Capecitabine

GSK

Preclinical

2 10

QBX258

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Sclerosis1 trial

MitoQ for Fatigue in Multiple Sclerosis

Terminated·OOregon Health and Science University·Phase 1/2·NCT03166800·9 enrolled

Breast Cancer1 trial

The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients

Unknown status·DD'Or Institute for Research and Education·N/A·NCT05146843·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Mitoquinone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mitoquinone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mitoquinone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oregon Health and Science University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOregon Health and Science University

Mitoquinone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Sclerosis1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News